Health Care · Pharmaceutical Preparations

AKBA Akebia Therapeutics, Inc. SEC Filings & Insider Trading Activity 2026

company
CIK 1517022113 filings
Russell 2000

AKBA at a glance

Akebia Therapeutics, Inc. (AKBA, SEC CIK 1517022) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on November 16, 2026 and Form 4 insider filings as recently as August 10, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2025 (FY2025), Akebia Therapeutics, Inc. (AKBA) reported revenue of $236.2 million (up 47.5% from FY2024) and a net loss of $5.3 million. Diluted EPS was -$0.02.
  • As of September 30, 2026, 27 institutional investment managers tracked by SignalX reported holding Akebia Therapeutics, Inc. (AKBA) shares worth $62.9 million in 13F-HR filings.
  • The most recent insider open-market sale reported on Form 4 was by Ostrowski Erik on June 29, 2026 of 56,019 shares at $1.11 per share.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$236.2M
+47.5% vs prior year
Insiders · 90 days
0 buys · 0 sells
No open-market trades
13F holders
27 funds
$62.9M · −3 vs prior quarter
Latest 8-K
Nov 16, 2026
Item 1.02 · Item 1.01 · Item 2.03 · Item 3.02 · Item 7.01 · Item 8.01

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Management Discussion & Analysis

  • Q3 revenue $36.9M, down 37% YoY from $58.8M
  • Net loss $14.4M vs $0.5M net income YoY, operating margin -31.1% vs 7.6%
  • Worst performer Auryxia revenue $20.0M, down 53% YoY from $42.5M
  • Cash $160.2M including restricted cash at September 30, down from $186.5M year-end 2025
  • Nine-month operating cash flow $(15.4)M vs $36.9M, outlook pressured by generics and lower Vafseo pricing in 2027

Risk Factors

  • Newly triggered regulatory risk: 2027 ESRD Rule creates quarterly Vafseo reimbursement adjustments after TDAPA expiration on January 1, 2027
  • Most material commercial update: Teva’s March 2026 generic Auryxia approval caused significant sales-volume reduction
  • Regulatory safety risk: Vafseo carries a boxed warning for increased death, myocardial infarction, stroke, and thromboembolic risks
  • Near-term market risk: Vafseo revenue was lower than anticipated in Q3 2026 as customers reduced inventory ahead of TDAPA expiration
  • Financial liquidity risk: $159.3 million cash depends on refinancing debt before principal payments begin January 1, 2027

AI summary of the AKBA 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 16, 2026Full analysis →

Item 1.02: Termination of a Material Definitive Agreement

  • Kreos Term Loan Facility terminated alongside the new loan agreement on January 29, 2024
  • Akebia’s obligations under the prior facility paid in full and discharged

Item 1.01: Entry into a Material Definitive Agreement

  • $60.0M initial senior secured term loan funded, with up to $80.0M additional discretionary borrowing
  • Net proceeds approximately $58.6M, used partly to repay Kreos’ $55.0M prior term loan

Item 2.03: Creation of a Direct Financial Obligation

  • Item 2.03 links to Item 1.01, indicating a material agreement created a direct financial obligation
  • Investor impact depends on the referenced agreement’s payment terms, amount, maturity and financing purpose

Item 3.02: Unregistered Sales of Equity Securities

  • Warrant terms described under Item 1.01 govern the unregistered equity issuance
  • Potential shareholder dilution depends on warrant count, exercise price, and expiration terms disclosed under Item 1.01

Item 7.01: Regulation FD Disclosure

  • Press release announces execution of a Loan Agreement
  • Financing terms and obligations require review of Exhibit 99.1

Item 8.01: Other Events

  • Debt repayment removes the Prior Loan Agreement from the company’s financing obligations
  • Management expects existing cash and operating revenues to fund the current plan for at least two years

Item EX-99.1: Item EX-99.1

  • $60 million senior secured tranche fully funded on November 12, 2026
  • Proceeds repaid BlackRock’s $55 million loan facility in full
Filed Nov 5, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Third-quarter results for period ended September 30, 2026 announced
  • Recent business highlights included alongside financial results

Item EX-99.1: Item EX-99.1

  • Q3 revenue $36.9M, down from $58.8M, driven by Auryxia revenue falling to $20.0M amid generic competition
  • Vafseo revenue $14.8M, while active patients reached approximately 11,500, up 140% year over year
Filed Oct 23, 2026Full analysis →

Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule

  • Nasdaq deficiency notice: AKBA closed below the $1.00 minimum bid for 30 consecutive business days
  • No immediate delisting: initial 180-day cure period runs through April 19, 2027

AI summaries of AKBA 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for AKBA

Don't miss the next AKBA filing

  • Alerts as it files. A push when AKBA files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut AKBA, by share count.
  • Ask anything. An AI agent that reads every AKBA filing and answers with sources.

AKBA alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
Butler John P.MAug 6, 2026-
Butler John P.MAug 6, 2026$0.63
Ostrowski ErikSellJun 29, 2026$1.11
ZUMWALT LEANNE MAJun 17, 2026-
ADAMS ADRIANAJun 17, 2026-
ZUMWALT LEANNE MAJun 17, 2026-
ROGERS MICHAEL WAJun 17, 2026-
Wolf MylesAJun 17, 2026-

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue-$160.2M$236.2M
Operating Income--$50.5M$23.5M
Net Income-$51.9M-$69.4M-$5.3M
Op. Margin--31.5%9.9%
Net Margin--43.3%-2.3%
Balance Sheet
Total Assets-$220.7M$376.6M
Equity-$30.6M-$49.2M$32.6M
ROE169.8%141.1%-16.4%
Per Share
EPS$-0.28$-0.33$-0.02
Cash Flow
Operating CF--$40.7M$68.0M
CapEx$0$33K$291K

Source: XBRL data in Akebia Therapeutics, Inc. (AKBA)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate AKBA share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
AKBA shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202627$62.9M
Q2 202630$81.2M
Q1 202629$95.6M
Q4 202525$125.9M
Q3 202526$220.3M
Q2 202527$259.3M
Q1 202525$81.3M
Q4 202421$50.6M
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
New Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 210 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

AKBA filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
8-KNov 16, 2026Analysis-
10-QNov 5, 2026Analysis
8-KNov 5, 2026Analysis-
8-KOct 23, 2026Analysis-
8-KOct 14, 2026Analysis-
4Aug 10, 2026--
8-KAug 5, 2026Analysis-
10-QAug 5, 2026Analysis
4Jul 1, 2026--
8-KJun 30, 2026Analysis-
4Jun 22, 2026--
8-KJun 22, 2026Analysis-
4Jun 22, 2026--
4Jun 22, 2026--
4Jun 22, 2026--
4Jun 22, 2026--
4Jun 22, 2026--
SC 13GMay 12, 2026-
8-KMay 7, 2026Analysis
10-QMay 7, 2026Analysis
4Apr 3, 2026--
8-KApr 1, 2026--
4Mar 5, 2026--
10-KFeb 26, 2026-
8-KFeb 26, 2026Analysis-

Related Health Care companies

All Health Care →

AKBA SEC filings: frequently asked questions

Which institutions hold AKBA stock?

As of September 30, 2026, the largest Akebia Therapeutics, Inc. (AKBA) holders among the 13F filers tracked by SignalX were BlackRock ($19.4 million), Vanguard Capital Management LLC ($10.4 million), AQR Capital Management ($5.8 million), Two Sigma Investments ($5.6 million), State Street Corp ($4.9 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What was AKBA's revenue in fiscal year 2025?

For the fiscal year ended December 31, 2025 (FY2025), Akebia Therapeutics, Inc. (AKBA) reported revenue of $236.2 million (up 47.5% from FY2024) and a net loss of $5.3 million. Diluted EPS was -$0.02. The figures come from the XBRL data in the 10-K.

What did AKBA report in its latest 8-K?

Akebia Therapeutics, Inc. (AKBA) filed an 8-K on November 16, 2026 reporting Item 1.02 (Termination of a Material Definitive Agreement), Item 1.01 (Entry into a Material Definitive Agreement), Item 2.03 (Creation of a Direct Financial Obligation), Item 3.02 (Unregistered Sales of Equity Securities), Item 7.01 (Regulation FD Disclosure) and Item 8.01 (Other Events). Kreos Term Loan Facility terminated alongside the new loan agreement on January 29, 2024.

What are the latest AKBA SEC filings?

Akebia Therapeutics, Inc. (AKBA) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on November 16, 2026 and a Form 4 insider filing on August 10, 2026.

What is AKBA's SEC CIK number?

Akebia Therapeutics, Inc. (AKBA)'s SEC Central Index Key (CIK) is 1517022. EDGAR lists every AKBA filing under that number.

Ask anything about AKBA

The research agent reads AKBA's filings, financials, insider trades and 13F holders, then answers with sources.